KR20190022928A - Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도 - Google Patents

Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도 Download PDF

Info

Publication number
KR20190022928A
KR20190022928A KR1020197005667A KR20197005667A KR20190022928A KR 20190022928 A KR20190022928 A KR 20190022928A KR 1020197005667 A KR1020197005667 A KR 1020197005667A KR 20197005667 A KR20197005667 A KR 20197005667A KR 20190022928 A KR20190022928 A KR 20190022928A
Authority
KR
South Korea
Prior art keywords
antibody
antibodies
seq
mammal
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197005667A
Other languages
English (en)
Korean (ko)
Inventor
에르콜레 라오
뱅상 미콜
단시 리
요헨 크루이프
매튜 데이비슨
Original Assignee
사노피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39313041&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20190022928(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 사노피 filed Critical 사노피
Publication of KR20190022928A publication Critical patent/KR20190022928A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020197005667A 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도 Ceased KR20190022928A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP07291259A EP2050764A1 (en) 2007-10-15 2007-10-15 Novel polyvalent bispecific antibody format and uses thereof
EP07291259.5 2007-10-15
US3712808P 2008-03-17 2008-03-17
US61/037,128 2008-03-17
PCT/US2008/079787 WO2009052081A2 (en) 2007-10-15 2008-10-14 Antibodies that bind il-4 and/or il-13 and their uses

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002319A Division KR101954596B1 (ko) 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도

Publications (1)

Publication Number Publication Date
KR20190022928A true KR20190022928A (ko) 2019-03-06

Family

ID=39313041

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020197005667A Ceased KR20190022928A (ko) 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도
KR1020147024155A Active KR101682373B1 (ko) 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도
KR1020107008006A Active KR101681909B1 (ko) 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도
KR1020167033258A Active KR101823859B1 (ko) 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도
KR1020187002319A Active KR101954596B1 (ko) 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020147024155A Active KR101682373B1 (ko) 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도
KR1020107008006A Active KR101681909B1 (ko) 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도
KR1020167033258A Active KR101823859B1 (ko) 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도
KR1020187002319A Active KR101954596B1 (ko) 2007-10-15 2008-10-14 Ｉｌ－４ 및/또는 ｉｌ－１３에 결합하는 항체 및 이들의 용도

Country Status (44)

Country Link
US (18) US8388965B2 (https=)
EP (12) EP2050764A1 (https=)
JP (5) JP5858616B2 (https=)
KR (5) KR20190022928A (https=)
CN (3) CN106986938B (https=)
AR (3) AR068861A1 (https=)
AU (5) AU2008312655B2 (https=)
BR (1) BRPI0818677B8 (https=)
CA (3) CA3015470C (https=)
CL (4) CL2008003037A1 (https=)
CR (5) CR11337A (https=)
CY (5) CY1114987T1 (https=)
DK (5) DK2574629T3 (https=)
DO (3) DOP2010000109A (https=)
ES (5) ES2647872T3 (https=)
GT (1) GT201000067A (https=)
HN (1) HN2010000710A (https=)
HR (5) HRP20140150T1 (https=)
HU (4) HUE036530T2 (https=)
IL (2) IL205005A (https=)
LT (4) LT2573121T (https=)
MA (1) MA31838B1 (https=)
MX (6) MX354150B (https=)
MY (1) MY171214A (https=)
NI (7) NI201000405A (https=)
NO (2) NO2574629T3 (https=)
NZ (3) NZ601342A (https=)
PA (1) PA8799001A1 (https=)
PE (1) PE20091382A1 (https=)
PH (2) PH12013501033B1 (https=)
PL (5) PL2573121T3 (https=)
PT (5) PT2573121T (https=)
PY (1) PY08038498A (https=)
RS (5) RS53175B (https=)
RU (4) RU2580049C2 (https=)
SG (4) SG10201913838RA (https=)
SI (5) SI2574629T1 (https=)
TN (1) TN2010000126A1 (https=)
TR (2) TR201810005T4 (https=)
TW (4) TWI616205B (https=)
UA (2) UA104130C2 (https=)
UY (1) UY31394A1 (https=)
WO (1) WO2009052081A2 (https=)
ZA (1) ZA201002069B (https=)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US20090148905A1 (en) * 2007-11-30 2009-06-11 Claire Ashman Antigen-binding constructs
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
SG2013061528A (en) * 2008-08-14 2015-03-30 Merck Sharp & Dohme Methods for purifying antibodies using protein a affinity chromatography
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
SG175077A1 (en) 2009-04-07 2011-11-28 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
WO2011030107A1 (en) * 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
EP2478013B1 (en) 2009-09-16 2018-10-24 F.Hoffmann-La Roche Ag Coiled coil and/or tether containing protein complexes and uses thereof
GB201000467D0 (en) * 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
FR2958936A1 (fr) * 2010-04-14 2011-10-21 Sanofi Aventis Proteine de fusion robo1-fc et son utilisation dans le traitement des tumeurs
EP2596114A4 (en) * 2010-07-14 2014-01-08 Amgen Inc IMMUNOGLOBULIN WITH DOMAIN INSERTION
SMT201700023T1 (it) 2010-08-02 2017-03-08 Regeneron Pharma Topi che producono proteine leganti vl
EP3252072A3 (en) 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
AR085404A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas de union a antigeno
MX342034B (es) 2011-02-28 2016-09-12 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos.
CN102675460B (zh) * 2011-02-28 2015-08-19 珠海市丽珠单抗生物技术有限公司 抗肿瘤坏死因子α的人源化抗体
TWI719112B (zh) * 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
PH12018501305B1 (en) * 2011-03-28 2022-11-04 Sanofi Sa Dual variable region antibody-like binding proteins having cross-over binding region orientation
TWI743461B (zh) * 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
UY34105A (es) 2011-06-03 2012-07-31 Lg Life Sciences Ltd Formulación líquida estable de etanercept
HUE047278T2 (hu) 2011-08-05 2020-04-28 Regeneron Pharma Humanizált univerzális könnyûláncú egerek
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
MX354902B (es) 2011-11-23 2018-03-23 Bioven 3 Ltd Proteínas recombinantes y sus usos terapéuticos.
WO2013103783A1 (en) * 2012-01-04 2013-07-11 Sanofi Us Murine il-13 antibodies
CA2861124A1 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
CN107099581B (zh) * 2012-03-27 2021-07-13 弗·哈夫曼-拉罗切有限公司 预测、诊断和治疗特发性肺纤维化的方法
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
KR20150030744A (ko) 2012-06-27 2015-03-20 에프. 호프만-라 로슈 아게 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
US9574004B2 (en) 2012-08-21 2017-02-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
PL3366705T3 (pl) 2012-09-12 2023-09-18 Genzyme Corporation FC zawierające polipeptydy o zmienionej glikozylacji i zmniejszonej funkcji efektorowej
CN105431453A (zh) 2012-11-01 2016-03-23 艾伯维公司 稳定的双重可变结构域免疫球蛋白制剂
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
HK1210713A1 (en) 2012-12-27 2016-05-06 Sanofi Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
US9701753B2 (en) 2013-03-11 2017-07-11 Genzyme Corporation Hyperglycosylated binding polypeptides
HK1207960A1 (en) 2013-03-12 2016-02-19 Abbvie Inc. Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
CN105530959B (zh) * 2013-03-15 2021-09-17 纪念斯隆-凯特琳癌症中心 多聚化技术
US11634502B2 (en) 2013-03-15 2023-04-25 Amgen Inc. Heterodimeric bispecific antibodies
JP2016522168A (ja) * 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
BR112016006929A2 (pt) 2013-10-11 2017-09-19 Hoffmann La Roche Anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, métodos de preparação de anticorpo, de tratamento de pacientes e de geração de um anticorpo, composição farmacêutica e uso do anticorpo
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150118251A1 (en) 2013-10-31 2015-04-30 Sanofi Specific anti-cd38 antibodies for treating human cancers
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CN105849124B (zh) 2013-12-20 2022-04-12 豪夫迈·罗氏有限公司 双重特异性抗体
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody
US20150225479A1 (en) * 2014-02-12 2015-08-13 Sanofi Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
UA117608C2 (uk) * 2014-02-21 2018-08-27 Дженентек, Інк. Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
WO2015143091A1 (en) 2014-03-19 2015-09-24 Genzyme Corporation Site-specific glycoengineering of targeting moieties
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
AU2015231025A1 (en) 2014-03-21 2016-09-15 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
TW201628647A (zh) 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體
SMT202000265T1 (it) 2014-07-11 2020-07-08 Genmab As Anticorpi che legano axl
EP3194446B1 (en) * 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
CA3205824A1 (en) 2014-10-09 2016-04-14 Genzyme Corporation Glycoengineered antibody drug conjugates
AU2015346150B2 (en) 2014-11-14 2021-08-19 Regeneron Pharmaceuticals, Inc. Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
EP3222637A4 (en) * 2014-11-21 2018-10-31 Astellas Pharma Inc. Novel bispecific antibody format
EP3227332B1 (en) 2014-12-03 2019-11-06 F.Hoffmann-La Roche Ag Multispecific antibodies
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
CN120988137A (zh) 2015-01-23 2025-11-21 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
MX2017011486A (es) * 2015-03-16 2018-06-15 Genentech Inc Métodos de detección y cuantificación de il-13 y sus usos en el diagnóstico y tratamiento de enfermedades asociadas a th2.
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
PL3319993T3 (pl) 2015-07-10 2020-07-27 Genmab A/S Specyficzne wobec AXL koniugaty przeciwciało-lek do leczenia raka
US10526413B2 (en) 2015-10-02 2020-01-07 Hoffmann-La Roche Inc. Bispecific antibodies specific for OX40
RS62437B1 (sr) 2015-10-25 2021-11-30 Sanofi Sa Trispecifični i/ili trivalentni vezujući proteini za prevenciju ili lečenje hiv infekcije
TW201720459A (zh) 2015-11-02 2017-06-16 妮翠斯製藥公司 Ntn1中和劑與抑制後生控制之藥物之組合治療
TW201736399A (zh) 2015-12-31 2017-10-16 財團法人生物技術開發中心 抗vegfr抗體及其應用
IL260289B (en) * 2016-01-08 2022-08-01 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
LT3443006T (lt) 2016-04-13 2023-10-25 Sanofi Trispecifiniai ir (arba) trivalenčiai rišantieji baltymai
CA3020633A1 (en) * 2016-04-13 2017-10-19 Sanofi Trispecific and/or trivalent binding proteins
JP6871948B2 (ja) 2016-04-27 2021-05-19 アッヴィ・インコーポレイテッド 抗ｉｌ−１３抗体を使用する、ｉｌ−１３活性が有害である疾患の治療方法
TW201808336A (zh) 2016-05-11 2018-03-16 賽諾菲公司 用抗ｍｕｃ１類美登素免疫綴合物抗體治療腫瘤的治療方案
WO2018011421A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
WO2018037092A1 (en) 2016-08-26 2018-03-01 Sanofi Multispecific antibodies facilitating selective light chain pairing
TW202300515A (zh) 2016-10-20 2023-01-01 法商賽諾菲公司 抗ｃｈｉｋｖ抗體及其用途
US20190276549A1 (en) 2016-11-01 2019-09-12 Genmab B.V. Polypeptide variants and uses thereof
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
KR102679324B1 (ko) 2017-01-05 2024-06-28 네트리 파르마 네트린-1 간섭 약물과 면역 관문 억제제 약물의 조합 치료
DK3583126T3 (da) 2017-02-17 2025-11-17 Sanofi Sa Multispecifikke bindingsmolekyler med specificitet for dystroglycan og laminin-2
KR102654105B1 (ko) * 2017-02-17 2024-04-04 사노피 디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
WO2018151841A1 (en) 2017-02-17 2018-08-23 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
KR101961871B1 (ko) * 2017-02-20 2019-07-17 주식회사 와이바이오로직스 신규 다중특이적 결합 단백질
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
MX2019012171A (es) * 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
EP3635005A1 (en) 2017-06-07 2020-04-15 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
WO2019009879A1 (en) * 2017-07-03 2019-01-10 Development Center For Biotechnology ANTI-VEGFR ANTIBODIES AND USES THEREOF
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
US10849960B2 (en) 2017-09-08 2020-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
BR112020007002A2 (pt) 2017-10-10 2020-11-17 Sanofi anticorpos anti-cd38 e métodos de uso
CN109705217B (zh) * 2017-10-25 2020-09-11 北京智仁美博生物科技有限公司 抗il-13抗体及其用途
CA3079946A1 (en) 2017-10-30 2019-05-09 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
CN119291194A (zh) 2018-01-12 2025-01-10 建新公司 用于定量多肽的方法
MA51666A (fr) 2018-01-24 2020-12-02 Genmab Bv Variants polypeptidiques et leurs utilisations
IL276286B2 (en) 2018-01-26 2025-07-01 Genzyme Corp FC variants with improved binding to FCRN and extended half-life
CA3096764A1 (en) * 2018-03-05 2019-09-12 Etablissement Francais Du Sang Recombinant single chain immunoglobulins
CA3093469A1 (en) * 2018-03-09 2019-09-12 The Brigham And Women's Hospital, Inc. Combination therapy for cardiovascular diseases
MX2020011552A (es) 2018-05-03 2020-11-24 Genmab Bv Combinaciones de variantes de anticuerpos y usos de las mismas.
EP3574915A1 (en) 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
US20200017600A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
US20240254252A1 (en) 2018-07-13 2024-08-01 Genmab A/S Trogocytosis-mediated therapy using cd38 antibodies
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
EP3860715A1 (en) 2018-10-04 2021-08-11 Genmab Holding B.V. Pharmaceutical compositions comprising bispecific anti-cd37 antibodies
JP7462621B2 (ja) 2018-10-09 2024-04-05 サノフイ 三重特異性抗ｃｄ３８、抗ｃｄ２８、および抗ｃｄ３結合タンパク質ならびにウイルス感染を処置するための使用方法
KR102330596B1 (ko) 2018-11-09 2021-11-26 아주대학교산학협력단 인간 il-4 수용체 알파에 대한 고친화도 인간 항체 및 이의 용도
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
NL2024544B1 (en) 2018-12-21 2021-03-15 Aim Immunotech Inc Compositions And Methods For Cancer Therapy
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CN110746507B (zh) * 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
MX2021010560A (es) 2019-03-06 2021-11-12 Regeneron Pharma Inhibidores de la via il-4/il-13 para una eficacia aumentada en el tratamiento de cancer.
CA3132587A1 (en) 2019-03-21 2020-09-24 Regeneron Pharmaceuticals, Inc. Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
CN120192414A (zh) 2019-04-03 2025-06-24 建新公司 具有降低的断裂的抗αβTCR结合多肽
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
JP7784898B2 (ja) 2019-05-24 2025-12-12 サノフイ 全身性硬化症を治療するための方法
EP3753954A1 (en) 2019-06-21 2020-12-23 Université de Franche-Comté Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells
BR112022000740A2 (pt) 2019-07-16 2022-07-05 Sanofi Biotechnology Métodos para tratamento ou prevenção de asma por administração de um antagonista de il-4r
CN115175932B (zh) 2019-07-16 2025-10-31 赛诺菲 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
WO2021016571A2 (en) 2019-07-25 2021-01-28 Genzyme Corporation Methods of treating antibody-mediated disorders with fcrn antagonists
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
GB201919062D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Antibody
EP4090365A1 (en) 2020-01-15 2022-11-23 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
JP2023512286A (ja) 2020-01-31 2023-03-24 サノフイ 抗体の肺送達
KR20220148235A (ko) 2020-02-28 2022-11-04 젠자임 코포레이션 최적화된 약물 접합을 위한 변형된 결합 폴리펩티드
AU2021229611A1 (en) 2020-03-03 2022-10-27 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
TW202146463A (zh) 2020-03-05 2021-12-16 法商賽諾菲公司 蛋白酶加工的分子
MX2022009936A (es) 2020-03-18 2022-09-12 Genmab As Anticuerpos que se unen al dominio v-set que contiene el inhibidor de activacion de celulas t 1 (b7h4).
US20230340040A1 (en) * 2020-04-14 2023-10-26 St. Jude Children's Research Hospital, Inc. Chimeric myd88 receptors
EP4138924A1 (en) 2020-04-24 2023-03-01 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfiri
AU2021258464A1 (en) 2020-04-24 2023-01-05 Sanofi Antitumor combinations containing anti-CEACAM5 antibody conjugates, trifluridine and tipiracil
MX2022013406A (es) 2020-04-24 2022-11-14 Sanofi Sa Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y cetuximab.
CA3181005A1 (en) 2020-04-24 2021-10-28 Sanofi Antitumor combinations containing anti-ceacam5 antibody conjugates and folfox
CN114957472B (zh) * 2020-06-22 2023-10-31 南京融捷康生物科技有限公司 抗IL-4Rα的单域抗体以及应用和药物
US20230340067A1 (en) * 2020-06-26 2023-10-26 St. Jude Children's Research Hospital, Inc. Methods of generating an activation inducible expression system in immune cells
JP2023534726A (ja) 2020-07-23 2023-08-10 ジェンマブ ビー．ブイ． 多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用
IL300835A (en) 2020-09-02 2023-04-01 Genmab As Antibody therapy
AU2021335257A1 (en) 2020-09-04 2023-03-09 Merck Patent Gmbh Anti-CEACAM5 antibodies and conjugates and uses thereof
AU2021379882A1 (en) 2020-11-10 2023-06-29 Sanofi Ceacam5 antibody-drug conjugate formulation
PE20231953A1 (es) * 2020-12-07 2023-12-06 UCB Biopharma SRL Anticuerpos multiespecificos y combinaciones de anticuerpos
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
WO2022234146A1 (en) 2021-05-07 2022-11-10 Genmab A/S PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES BINDING TO B7H4 and CD3
EP4347640A1 (en) 2021-05-27 2024-04-10 Sanofi Fc variant with enhanced affinity to fc receptors and improved thermal stability
CA3225636A1 (en) 2021-07-02 2023-01-05 Merck Patent Gmbh Anti-protac antibodies and complexes
TW202311743A (zh) * 2021-07-26 2023-03-16 日商電化股份有限公司 包含人類化抗體之試劑
CA3229324A1 (en) * 2021-08-20 2023-02-23 Beatrice DROUET Mrna vaccines comprising il-4 and/or il-13 rna and uses thereof
AU2022382383A1 (en) 2021-11-05 2024-06-20 Eli Lilly And Company Antitumor combinations containing anti-ceacam5 antibody-drug conjugates and anti-vegfr-2 antibodies
US20230220089A1 (en) 2021-12-30 2023-07-13 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
US20250179210A1 (en) 2022-03-09 2025-06-05 Merck Patent Gmbh Anti-ceacam5 antibodies and conjugates and uses thereof
EP4245772A1 (en) 2022-03-18 2023-09-20 Netris Pharma Anti-netrin-1 antibody to treat liver inflammation
EP4249509A1 (en) 2022-03-22 2023-09-27 Netris Pharma Anti-netrin-1 antibody against arthritis-associated pain
KR20250017240A (ko) 2022-05-27 2025-02-04 사노피 FC-조작을 갖는 NKp46 및 BCMA 변이체에 결합하는 자연 살해(NK) 세포 관여자
EP4540284A2 (en) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 13 and methods of use
WO2024089609A1 (en) 2022-10-25 2024-05-02 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function
CN121240880A (zh) 2022-12-27 2025-12-30 默克专利股份有限公司 Vhh抗protac抗体和复合物
EP4413995A1 (en) 2023-02-07 2024-08-14 Université de Franche-Comté Anti-cd123 chimeric antigen receptors t cells for use in the treatement of autoimmune diseases
IL322938A (en) 2023-02-27 2025-10-01 South Australian Health And Medical Res Institute Limited Anti-netrin-1 monoclonal antibody for the treatment of endometrial disease and associated pain
JP2026508856A (ja) 2023-03-01 2026-03-13 サノフイ Ｃｅａｃａｍ５を発現する神経内分泌がんを処置するための抗ｃｅａｃａｍ５免疫複合体の使用
EP4427763A1 (en) 2023-03-06 2024-09-11 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-vegfr-2 antibodies and anti-pd1/pd-l1 antibodies
KR20250169564A (ko) 2023-03-23 2025-12-03 사노피 암 치료법에서 환자 선택을 위한 CEACAM5 mRNA 검정
EP4434586A1 (en) 2023-03-23 2024-09-25 Xenothera Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancer and composition thereof
TW202509071A (zh) 2023-05-12 2025-03-01 丹麥商珍美寶股份有限公司 能夠與ｏｘ４０結合之抗體、其變異體及其用途
AU2024272851A1 (en) * 2023-05-15 2026-01-15 Sthria Sciences Limited Liability Company A method of treating autoimmune disease
EP4719483A1 (en) 2023-06-05 2026-04-08 Sanofi Antitumor combinations containing anti-ceacam5 antibody-drug conjugates, anti-pd1/pd-l1 antibodies and anti-ctla4 antibodies
WO2025049348A1 (en) * 2023-08-25 2025-03-06 Triveni Bio, Inc. Klk5/7 + il-13 targeting antibodies and uses thereof
WO2025049346A1 (en) * 2023-08-25 2025-03-06 Triveni Bio, Inc. Klk5/7 + th2 targeting antibodies and uses thereof
WO2025049347A1 (en) * 2023-08-25 2025-03-06 Triveni Bio, Inc. Klk5/7 + il-4 targeting antibodies and uses thereof
AU2024334289A1 (en) 2023-08-25 2026-04-09 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025073856A1 (en) 2023-10-04 2025-04-10 Xenothera Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers
TW202535925A (zh) 2023-10-25 2025-09-16 比利時商艾伯霖克斯公司 具有增強的Ｆｃ受體結合之Ｆｃ結構域變體
WO2025166138A1 (en) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Klk5/7 + tslp targeting antibodies and uses thereof
WO2025166146A1 (en) * 2024-02-02 2025-08-07 Triveni Bio, Inc. Klk5/7 + ox40 targeting antibodies and uses thereof
WO2025242845A1 (en) 2024-05-22 2025-11-27 Merck Patent Gmbh Colorectal cancer treatment
WO2026022712A1 (en) 2024-07-23 2026-01-29 Sanofi Cereblon ligase modulator and bcma nk cell engager combination therapy
EP4722240A1 (en) 2024-10-07 2026-04-08 Xenothera Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers and compositions thereof

Family Cites Families (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
AU631802B2 (en) 1988-06-14 1992-12-10 Cetus Oncology Corporation Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
IL94611A (en) 1989-06-05 1994-12-29 Organogenesis Inc Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (en) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Chimeric antibodies with receptor binding ligands in place of their constant region
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
DE69133036T2 (de) 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DK0598877T3 (da) 1992-06-09 2000-02-21 Hoppe Ag Falle og dørlås
CA2141602A1 (en) 1992-08-26 1994-03-03 Philip Leder Use of the cytokine ip-10 as an anti-tumor agent
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US5928904A (en) * 1993-09-07 1999-07-27 Smithkline Beecham Corporation DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
US20020193575A1 (en) 1993-09-07 2002-12-19 Smithkline Beecham P.L.C. Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
RU2162711C2 (ru) * 1993-09-07 2001-02-10 Смитклайн Бичам Корпорейшн Рекомбинантные il4-антитела, используемые для лечения нарушений, связанных с действием il4
WO1995007301A1 (en) 1993-09-07 1995-03-16 Smithkline Beecham Corporation Recombinant il4 antibodies useful in treatment of il4 mediated disorders
WO1995009917A1 (en) * 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5597710A (en) 1994-03-10 1997-01-28 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5705154A (en) * 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US6165463A (en) 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
BR9606706A (pt) 1995-10-16 1999-04-06 Unilever Nv Análogo de fragmento de anticorpo biespecífico ou bivalente uso processo para produzir o mesmo
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
AU5711196A (en) 1996-03-14 1997-10-01 Human Genome Sciences, Inc. Apoptosis inducing molecule i
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
GB9625899D0 (en) * 1996-12-13 1997-01-29 Glaxo Group Ltd Substances and their uses
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CA2309541C (en) 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
WO2000018435A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
HUP0200575A3 (en) * 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
JP2003531588A (ja) 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
CA2409991A1 (en) * 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
WO2002008293A2 (en) * 2000-07-25 2002-01-31 Immunomedics Inc. Multivalent target binding protein
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
RU2430927C2 (ru) * 2000-10-20 2011-10-10 Тугаи Сейяку Кабусики Кайся Агонистическое соединение, способное специфически узнавать и поперечно сшивать молекулу клеточной поверхности или внутриклеточную молекулу
US20040023338A1 (en) 2001-10-26 2004-02-05 Heavner George A. IL-4 mutein proteins, antibodies, compositions, methods and uses
CA2464695A1 (en) 2001-10-26 2003-05-01 Centocor, Inc. Il-13 mutein proteins, antibodies, compositions, methods and uses
AU2003243189B2 (en) 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
WO2004094613A2 (en) 2003-04-22 2004-11-04 Ibc Pharmaceuticals Polyvalent protein complex
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
BRPI0416603A (pt) * 2003-11-07 2007-01-30 Immunex Corp anticorpo que se liga ao receptor interleucina-4 (il-4) humano
PL3718564T3 (pl) 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
US7652146B2 (en) 2004-02-06 2010-01-26 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-carboxamides useful as kinase inhibitors
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
EP1723173B1 (en) 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Il-4/il-13 specific polypeptides and therapeutic uses thereof
GB0411186D0 (en) * 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
PT1765397E (pt) * 2004-05-25 2013-02-04 Tactic Pharma Llc Anticorpos inibidores que se ligam ao complexo ativador plasminogénico do tipo uroquinasa (upa) e seu receptor (upar)
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
GB0414799D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Immunoglobulins
WO2006042333A2 (en) 2004-10-12 2006-04-20 Xencor, Inc. Prediction and assessment of immunogenicity
TWI306862B (en) * 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
US20090041783A1 (en) * 2005-04-28 2009-02-12 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
GB0514319D0 (en) * 2005-07-13 2006-06-14 Secr Defence Antibodies for anthrax
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006296399B2 (en) 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
WO2007045477A2 (en) * 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
EP2441838A3 (en) * 2006-01-24 2013-07-10 Domantis Limited Fusion proteins that contain natural junctions
CA2646626A1 (en) * 2006-03-22 2007-09-27 Apogenix Gmbh Antibody specific for human il-4 for the treatment of cancer
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
TWI719112B (zh) * 2011-03-16 2021-02-21 賽諾菲公司 雙重ｖ區類抗體蛋白質之用途
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
TW201628647A (zh) * 2014-06-27 2016-08-16 賽諾菲公司 抗－ｉｌ４－ｉｌ１３雙特異性抗體

Also Published As

Publication number Publication date
US8388965B2 (en) 2013-03-05
TN2010000126A1 (en) 2011-09-26
RU2015141428A3 (https=) 2019-04-30
US20250313651A1 (en) 2025-10-09
RS57060B1 (sr) 2018-05-31
SG10201913838RA (en) 2020-03-30
JP5858616B2 (ja) 2016-02-10
CY1120108T1 (el) 2018-12-12
AU2013203324A1 (en) 2013-05-02
AU2013203328B9 (en) 2017-02-02
US20130236462A1 (en) 2013-09-12
PT2573121T (pt) 2017-11-21
AU2013203339B9 (en) 2017-02-02
KR101823859B1 (ko) 2018-02-01
JP2011501671A (ja) 2011-01-13
RU2015141428A (ru) 2017-04-04
US20130259866A1 (en) 2013-10-03
AU2013203339B2 (en) 2017-01-05
LT2574630T (lt) 2018-07-25
UY31394A1 (es) 2009-05-29
NO2574629T3 (https=) 2018-04-21
MX363634B (es) 2019-03-28
US10759871B2 (en) 2020-09-01
US9732162B2 (en) 2017-08-15
RS56914B1 (sr) 2018-05-31
CA3071750A1 (en) 2009-04-23
CN106986938A (zh) 2017-07-28
US20230235088A1 (en) 2023-07-27
MA31838B1 (fr) 2010-11-01
EP2573119A1 (en) 2013-03-27
CL2013002040A1 (es) 2014-01-24
DK2573119T3 (en) 2018-04-16
PH12013501033A1 (en) 2015-05-25
NI201000401A (es) 2010-09-07
EP2574629B1 (en) 2017-11-22
PT2574629T (pt) 2018-02-23
EP2573116A1 (en) 2013-03-27
AU2013202389A1 (en) 2013-05-02
HRP20181085T1 (hr) 2018-09-07
RU2721236C2 (ru) 2020-05-18
CA2702473C (en) 2018-10-09
ES2660152T3 (es) 2018-03-21
RU2580049C2 (ru) 2016-04-10
AU2013203339A1 (en) 2013-05-02
TW201536321A (zh) 2015-10-01
CN101827863B (zh) 2017-03-22
AR068861A1 (es) 2009-12-09
CY1119875T1 (el) 2018-06-27
CA3071750C (en) 2022-06-14
CY1114987T1 (el) 2016-12-14
MX354666B (es) 2018-03-15
AU2013203328B2 (en) 2017-01-05
PL2573119T3 (pl) 2018-07-31
US20130236461A1 (en) 2013-09-12
TW201825117A (zh) 2018-07-16
ES2679281T3 (es) 2018-08-23
TR201802225T4 (tr) 2018-03-21
NO2573121T3 (https=) 2018-01-20
CL2013002039A1 (es) 2014-03-07
US9738728B2 (en) 2017-08-22
HRP20180517T1 (hr) 2018-05-04
EP2050764A1 (en) 2009-04-22
US20100226923A1 (en) 2010-09-09
CA2702473A1 (en) 2009-04-23
NI201000402A (es) 2010-09-07
DK2574630T3 (en) 2018-07-30
DOP2013000302A (es) 2014-02-16
HRP20180320T1 (hr) 2018-04-06
HN2010000710A (es) 2013-07-22
UA104130C2 (uk) 2014-01-10
SG10201602770UA (en) 2016-05-30
US11453727B2 (en) 2022-09-27
AU2013203324B2 (en) 2017-01-19
LT2574629T (lt) 2018-03-12
EP2573119B1 (en) 2018-01-03
PT2205640E (pt) 2014-02-25
DK2574629T3 (en) 2018-02-26
EP2573117A1 (en) 2013-03-27
EP2205640A2 (en) 2010-07-14
NZ729148A (en) 2021-12-24
CL2008003037A1 (es) 2009-03-06
JP2018078907A (ja) 2018-05-24
BRPI0818677B1 (pt) 2019-11-12
ES2664476T3 (es) 2018-04-19
HUE038556T2 (hu) 2018-10-29
WO2009052081A4 (en) 2009-07-23
MX363901B (es) 2019-04-08
EP2573118A1 (en) 2013-03-27
CY1120033T1 (el) 2018-12-12
JP2016006086A (ja) 2016-01-14
EP3686220A1 (en) 2020-07-29
KR101682373B1 (ko) 2016-12-06
TWI616205B (zh) 2018-03-01
WO2009052081A2 (en) 2009-04-23
EP2574630A1 (en) 2013-04-03
EP2573115A1 (en) 2013-03-27
US20130209469A1 (en) 2013-08-15
US20130236460A1 (en) 2013-09-12
MX2010003290A (es) 2010-04-30
AU2013202389B9 (en) 2017-02-02
PT2574630T (pt) 2018-07-17
SG185303A1 (en) 2012-11-29
CA3015470A1 (en) 2009-04-23
TR201810005T4 (tr) 2018-08-27
PH12013501032A1 (en) 2015-05-18
CR20150103A (es) 2015-04-14
SI2205640T1 (sl) 2014-04-30
RU2015141418A3 (https=) 2019-05-14
IL205005A0 (en) 2010-11-30
LT2573119T (lt) 2018-04-10
CR20150101A (es) 2015-04-14
BRPI0818677B8 (pt) 2021-05-25
CR20150102A (es) 2015-04-30
NI201000405A (es) 2010-09-07
CA3015470C (en) 2022-01-18
HUE037205T2 (hu) 2018-08-28
CN106986938B (zh) 2021-07-09
PL2205640T3 (pl) 2014-05-30
RS56553B1 (sr) 2018-02-28
HRP20171765T1 (hr) 2017-12-29
CL2012003196A1 (es) 2013-01-25
ES2447915T3 (es) 2014-03-13
CY1120887T1 (el) 2019-12-11
DK2205640T3 (en) 2014-02-24
EP2574629A1 (en) 2013-04-03
CR20150654A (es) 2016-02-08
AR122834A2 (es) 2022-10-12
JP2015231382A (ja) 2015-12-24
ES2647872T3 (es) 2017-12-27
JP6126653B2 (ja) 2017-05-10
US20130243777A1 (en) 2013-09-19
MY171214A (en) 2019-10-02
SG10201913836SA (en) 2020-03-30
IL205005A (en) 2016-11-30
SI2574630T1 (en) 2018-08-31
RU2010119521A (ru) 2011-11-27
JP6280526B2 (ja) 2018-02-14
EP2574626A1 (en) 2013-04-03
RU2015141418A (ru) 2017-04-04
AU2013202389B2 (en) 2017-01-05
PA8799001A1 (es) 2009-07-23
SI2574629T1 (en) 2018-03-30
NI201000404A (es) 2010-09-07
PL2573121T3 (pl) 2018-01-31
AU2013203324C1 (en) 2017-03-30
JP2016006087A (ja) 2016-01-14
HUE036530T2 (hu) 2018-07-30
RS57396B1 (sr) 2018-09-28
KR101681909B1 (ko) 2016-12-05
NI201000406A (es) 2010-09-07
HUE038444T2 (hu) 2018-10-29
AU2008312655A1 (en) 2009-04-23
SI2573121T1 (en) 2018-01-31
TWI616206B (zh) 2018-03-01
IL249289A0 (en) 2017-01-31
NI201000403A (es) 2010-09-07
PT2573119T (pt) 2018-04-04
PL2574629T3 (pl) 2018-05-30
EP2573121B1 (en) 2017-08-23
SI2573119T1 (en) 2018-05-31
MX363638B (es) 2019-03-28
PL2574630T3 (pl) 2018-09-28
US20130251718A1 (en) 2013-09-26
DK2573121T3 (en) 2017-12-04
UA118949C2 (uk) 2019-04-10
TWI619508B (zh) 2018-04-01
TW201536322A (zh) 2015-10-01
CN101827863A (zh) 2010-09-08
US20130243778A1 (en) 2013-09-19
US20180030156A1 (en) 2018-02-01
AU2013203328A1 (en) 2013-05-02
EP2205640B1 (en) 2013-11-20
NI201000040A (es) 2010-09-07
NZ584658A (en) 2012-08-31
BRPI0818677A2 (pt) 2015-04-14
EP2574630B1 (en) 2018-04-18
TW200932263A (en) 2009-08-01
RU2705551C2 (ru) 2019-11-07
US20140023649A1 (en) 2014-01-23
CN113480647B (zh) 2025-03-28
KR101954596B1 (ko) 2019-03-07
PH12013501032B1 (en) 2015-05-18
US20210047437A1 (en) 2021-02-18
US20130243776A1 (en) 2013-09-19
PY08038498A (es) 2014-08-01
EP2573121A1 (en) 2013-03-27
KR20160142889A (ko) 2016-12-13
JP6126652B2 (ja) 2017-05-10
GT201000067A (es) 2012-04-12
US20130251716A1 (en) 2013-09-26
LT2573121T (lt) 2017-12-11
KR20100067669A (ko) 2010-06-21
KR20140112574A (ko) 2014-09-23
US20130251717A1 (en) 2013-09-26
WO2009052081A3 (en) 2009-06-04
NZ709353A (en) 2018-06-29
DOP2013000301A (es) 2014-02-16
PH12013501033B1 (en) 2018-12-14
KR20180014189A (ko) 2018-02-07
RU2488595C2 (ru) 2013-07-27
DOP2010000109A (es) 2010-05-31
CR11337A (es) 2010-04-21
US20130236463A1 (en) 2013-09-12
RU2013120318A (ru) 2014-11-10
MX354150B (es) 2018-02-15
CN113480647A (zh) 2021-10-08
ZA201002069B (en) 2010-12-29
HRP20140150T1 (hr) 2014-03-28
PE20091382A1 (es) 2009-10-14
AR122833A2 (es) 2022-10-12
RS53175B (sr) 2014-06-30
NZ601342A (en) 2014-02-28
AU2008312655B2 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
US20250313651A1 (en) Antibodies that bind il-4 and/or il-13 and their uses
HK1183885A (en) Antibodies that bind il-4 and/or il-13 and their uses
HK1183497A (en) Antibodies that bind il-4 and/or il-13 and their uses
HK1183675A (en) Antibodies that bind il-4 and/or il-13 and their uses
HK1183883B (en) Antibodies that bind il-4 and/or il-13 and their uses
HK1183879B (en) Antibodies that bind il-4 and/or il-13 and their uses
HK1183879A (en) Antibodies that bind il-4 and/or il-13 and their uses
HK1183498A (en) Antibodies that bind il-4 and/or il-13 and their uses
HK1183498B (en) Antibodies that bind il-4 and/or il-13 and their uses
HK1183495A (en) Antibodies that bind il-4 and/or il-13 and their uses

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190226

Application number text: 1020187002319

Filing date: 20180124

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190327

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190919

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20191203

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190919

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I